Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia/reperfusion-induced acute lung injury in rats

Chen, S; Chen, X; Wu, Xianping; Su, Wei; Han, Wei; Lin, Jie; Kang, Mingqiang; Chen, L

doi:10.1038/gt.2016.64

Cited by 40 publications

(50 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But the exact mechanism in inflammation and immunosuppression is not clear. MSCs could induce peripheral immune tolerance and migrate to the damaged tissue, could inhibit pro-inflammatory cytokines release and promote the damaged cells survival (67), and MSCs achieved remarkable therapeutic effects in the treatment of acute lung injury (13,45), myocardial infarction (1), acute renal failure (56), cerebral ischemia (59), and Alzheimer's disease (31). It found that MSCs have inflammatory regulatory functions.…”

Section: Abstract: Angiogenesis Anti-apoptosis Immunomodulatory Mementioning

confidence: 99%

The research progress of mesenchymal stem cells in the treatment of traumatic brain injury

Yang²,

Dong³

et al. 2017

Turkish Neurosurgery

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is the leading cause of mortality and morbidity in children and adults throughout the world. It is urgent to ameliorate TBI damage and reduce the disability and case-fatality rate. Stem cell therapy is another medical revolution after drug and surgical medication. Mesenchymal stem cells (MSCs) are a class of cells with significant self-renewal and multi-lineage differentiation properties and be favorable for the treatment of various diseases and injuries, it could be envisioned that MSCs transplantation may be a promising treatment for TBI. Currently, stem cell therapy has shown promising effects in the treatment of many diseases. In this article, we will review the characteristics of MSCs, MSCs for neuronal function restoration, the properties of immune-modulatory of MSCs, and the anti-apoptotic effects of MSCs, the angiogenesis effect of MSCs,and the safety issues in MSCs therapy in TBI.

show abstract

Section: Abstract: Angiogenesis Anti-apoptosis Immunomodulatory Mementioning

confidence: 99%

The research progress of mesenchymal stem cells in the treatment of traumatic brain injury

Yang²,

Dong³

et al. 2017

Turkish Neurosurgery

View full text Add to dashboard Cite

show abstract

“…Additionally, fibroblasts have emerged as regulators of inflammation resolution that act by producing proresolving peroxisome proliferator-activated receptor-g ligands (19), as well as COX-2 and PGD 2 (20). Recently, accumulating evidence has demonstrated that the growth factors secreted from fibroblasts can promote alveolar barrier function (21)(22)(23), alleviate pulmonary edema (21,24), and protect against lung injury from various stresses, such as LPS (25,26), ventilator (24) and ischemia/reperfusion-induced lung injury (27,28). Thus, lung fibroblasts have emerged as essential players in the resolution of ARDS.…”

mentioning

confidence: 99%

Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50–Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome

Gao

Zhang

Luo

et al. 2017

The Journal of Immunology

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) is a severe illness characterized by uncontrolled inflammation. The resolution of inflammation is a tightly regulated event controlled by endogenous mediators, such as resolvin D1 (RvD1). Cyclooxygenase-2 (COX-2) has been reported to promote inflammation, along with PGE2, in the initiation of inflammation, as well as in prompting resolution, with PGD2 acting in the later phase of inflammation. Our previous work demonstrated that RvD1 enhanced COX-2 and PGD2 expression to resolve inflammation. In this study, we investigated mechanisms underlying the effect of RvD1 in modulating proresolving COX-2 expression. In a self-limited ARDS model, an LPS challenge induced the biphasic activation of COX-2, and RvD1 promoted COX-2 expression during the resolution phase. However, it was significantly blocked by treatment of a NF-κB inhibitor. In pulmonary fibroblasts, NF-κB p50/p50 was shown to be responsible for the proresolving activity of COX-2. Additionally, RvD1 potently promoted p50 homodimer nuclear translocation and robustly triggered DNA-binding activity, upregulating COX-2 expression via lipoxin A4 receptor/formyl peptide receptor 2. Finally, the absence of p50 in knockout mice prevented RvD1 from promoting COX-2 and PGD2 expression and resulted in excessive pulmonary inflammation. In conclusion, RvD1 expedites the resolution of inflammation through activation of lipoxin A4 receptor/formyl peptide receptor 2 receptor and NF-κB p50/p50–COX-2 signaling pathways, indicating that RvD1 might have therapeutic potential in the management of ARDS.

show abstract

“…Interestingly, we achieved that expression level of HGF, a crucial factor for hepatogenic differentiation, was noticeably increased in hESC-MSCs, compared to hBM-MSCs and hASCs. Considering that HGF-overexpressing hMSCs are effective for tissue regeneration (8,9), it is crucial to express endogenously high HGF. And then, we investigated whether hESC-MSCs have better hepatogenic differentiation potential than hASCs.…”

Section: Discussionmentioning

confidence: 99%

Human embryonic stem cell-derived mesenchymal stem cells have potential of high differentiation into hepatocyte-like cells through increased level of hepatocyte growth factor

Lee

Yoon

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: As the aging society progresses, more patients are waiting for liver transplantation. However, the function of existing bio artificial liver is insufficient. Recently, research has been focused on stem cells to regenerate damaged liver. Most of all, the obstacle to the commercialization of widely used human adipose tissue-derived stem cells (hASCs) therapy is the limited supply of cells with consistent quality although most cell source of current stem cell therapy is hASCs. In this study, we attempt to differentiate human embryonic stem cell-derived mesenchymal stem cells (hESC-MSCs) into hepatocyte-like cells and tested whether hESC-MSCs have a potential of liver regeneration as a source of cell therapy, considering that they have characteristics of high differentiation rates, unlimited proliferation possibility from a single colony, and homogenicity.Methods: hESC-MSCs and hASCs were cultured under condition of hepatogenic differentiation in vitro. And then various experiments including quantitative real-time PCR, immunoblotting, ELISA, immunofluorescence, Periodic acid-Schiff staining and flow cytometry analysis were performed to evaluate expression level of HGF and the extent of differentiation into hepatocyte-like cells.Results: We found that hepatocyte growth factor (HGF), important for maintaining hepatocyte activity, is highly expressed in hESC-MSCs. Besides, it was confirmed that the expression of ALB, TDO2, and CYP2E1, which are the hepatocyte-specific genes when hepatogenic differentiation was performed under conditions even without HGF in hESC-MSCs, was higher than that when hASCs was differentiated into hepatocytes. Likewise, we concluded that hESC-MSCs could be well-differentiated into hepatocyte-like cells compared to hASCs through staining data.Conclusions: We propose that hESC-MSCs have a promising potential as a commercial cell therapy source to treat liver failure in view of the limited available cell sources for stem cell therapy.

show abstract

Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia/reperfusion-induced acute lung injury in rats

Cited by 40 publications

References 42 publications

The research progress of mesenchymal stem cells in the treatment of traumatic brain injury

The research progress of mesenchymal stem cells in the treatment of traumatic brain injury

Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50–Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome

Human embryonic stem cell-derived mesenchymal stem cells have potential of high differentiation into hepatocyte-like cells through increased level of hepatocyte growth factor

Contact Info

Product

Resources

About